Top Pharma and Innovative Biotech Presentations at the 2024 Immuno-Oncology Summit
Discover Presentations from industry pioneers, thought leaders, and influencers as they converge to showcase the latest breakthroughs in cancer immunology.
Development of ex vivo
Precision Gene-Engineered B Cell-Medicines That Produce Highly Active and
Sustained Levels of Transgenic Anti-Tumor Biologics
Sean P. Arlauckas, PhD,
Associate Director, Cell Therapy Platform, Be Biopharma Inc.
Uncovering Heterogeneity
in Specific Immune Cell Populations in the Tumor Microenvironment
Shahin Aslam, Associate
Principal Scientist, Merck
Combined PD-L1/TGFβ
Blockade Allows Expansion and Differentiation of Stem Cell–Like CD8 T Cells
in Immune-Excluded Tumors
Alessandra Castiglioni,
PhD, Scientific Manager, Cancer Immunology, Genentech Inc.
TALEN-Based Platform for
Generation of Gene-Edited iPSC-Derived Natural Killer Cells with Improved
Functions
An-Ping Chen, PhD,
Associate Director, R&D, Cytovia Therapeutics
Best Practices and
Considerations for Clinical Pharmacology and Pharmacometric Aspects for
Optimal Development of CAR T Therapies
Nagendra V. Chemuturi,
PhD, Senior Director, Eli Lilly and Company
The Advantages of CAR
Tscm-Rich Allogeneic Approaches in Oncology
Julia A Coronella, PhD,
VP Immuno Oncology, Immuno Oncology, Poseida Therapeutics Inc
Lymph Node–Targeted
Vaccine-Boosting of TCR T Cell Therapy Enhances Antitumor Function and
Eradicates Solid Tumors
Peter C. DeMuth, PhD,
CSO, Elicio Therapeutics
ABBV-184: A Novel
Survivin-Specific CD3 Bispecific T Cell Engager Is Active against Both Solid
Tumor and Hematological Malignancies
Feng Dong, PhD,
Principal Research Scientist II, Foundational Immunology, AbbVie Cambridge
Research Center
Benefit and Risk
Considerations for Dose Optimization in Immuno-Oncology
Mohamed Elmeliegy, PhD,
Director Clinical Pharmacology, Clinical Pharmacology, Pfizer Inc.
A Phase 1/2 Clinical
Trial of KVA12123, an Engineered IgG1 Targeting VISTA, as Monotherapy and in
Combination with Pembrolizumab in Patients with Advanced Solid Tumors
Thierry Guillaudeux, PhD,
CSO, Kineta, Inc.
In
Vivo Generation of CAR T and NK Cells Utilizing an
Engineered Lentiviral Vector
Philip R. Johnson, MD, CEO, Interius
Biotherapeutics
Engineering Next-Gen CAR
T Cells: Leveraging mRNA for Optimal T Cell Design
Stella Khiew, PhD, Senior Scientist,
Merck & Co.
Therapeutic Potency of
SAIL66—A Next-Generation T Cell Engager—Against CLDN6-Positive Tumors
Naoki Kimura, PhD,
Scientist, Discovery Pharmacology, Chugai Pharmaceutical Co. Ltd.
Development of a
High-Throughput 3D Culture Model of Immune-Excluded Tumor Microenvironments
Joanna Y. Lee, PhD,
Principal Scientist, Biochemical & Cellular Pharmacology, Genentech
An Autologous Process
Generates Genetically Engineered T Cells with Enriched T Memory Stem Cells
and Improved Quality Attributes
Yijun Liu, PhD, Associate
Director, Cell Biology, Kite Pharma
Infiltrating Solid Tumor
Stromal Barriers with Trispecific Antibodies
Maria P. MacWilliams,
PhD, Vice President Molecular Biology, Tavotek Biotherapeutics
KEYNOTE PRESENTATION:
mRNA Therapeutics in Cancer: Coming of Age
Michelle Brown, MD, PhD, Vice President, Moderna, Inc.
Ramifications of
Tethering T Cell-Activating Cytokines to the Surface of Tumor Cells
John B. Mumm, PhD,
Founder & CEO, Deka Biosciences
Intensification of iPSC
GdT/NK Product Manufacturing for IO
Yu Qian, PhD, Senior
Scientist & Analytical Lead, Cellular Product Development, Takeda
Pharmaceuticals Inc.
Computational Approaches
to Identifying Targetable Antigens for Personalized Cancer Immunotherapies
Thomas Trolle, PhD,
Director, Bioinformatics & AI/ML, Evaxion Biotech A/S
Design Meets Biology:
Importance of Avidity versus Geometry in Engineering T Cell Engagers
Even Walseng, PhD,
Associate Director Biologics Engineering, Biologics Engineering, AstraZeneca
Translational PK/PD and
the First-in-Human Dose Selection of a PD1/IL15 Targeted Cytokine: An
Engineered Recombinant Fusion Protein for Cancer Immunotherapy
Rajbharan Yadav, PhD,
Senior Principal Scientist, Development Sciences, Genentech
Personalized
Neoantigen-Based DNA Vaccine in Combination with Pembrolizumab for Treating
Patients with Advanced Hepatocellular Cancer
Jian Yan, PhD, Vice
President, Research & Discovery, Geneos Therapeutics